Please assess the completion status of the following clinical trial:

Trial Title: Denosumab Versus Zoledronic Acid in Thalassemia-Induced Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Willing to participate in the study~* Age 18 years old or older~* Eastern Cooperative Oncology Group Performance Status less than or equal 2~Exclusion Criteria:~* Age less than 18 years old~* Not willing to participate in the study~* Vulnerable subjects or Eastern Cooperative Oncology Group Performance Status 3 or 4

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Denosumab (Type: ACTIVE_COMPARATOR): Denosumab 60 MG/ML Prefilled Syringe~Denosumab Dose: 60 milligrams, subcutaneous injection, every 6 months (twice a year)
- Zoledronic Acid (Type: ACTIVE_COMPARATOR): Zoledronic Acid 5Mg/Bag 100Ml Inj~Zoledronic acid will be 5 milligrams, Intravenous injection, once a year

Based on this trial design, predict the completion outcome and termination type (if applicable).